Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis
Authors' conclusion
TNFRSF14 emerges as a promising biomarker and therapeutic target for the early detection and specific treatment of DP, paving the way for improved patient outcomes.
Study context
- Population
- Large-scale clinical and genetic datasets; diabetic polyneuropathy (DP)
- Outcome
- Proteins linked to DP
Methodological detailsprospective cohorts, genetic analysis, single-cell sequencing
- Prospective cohorts
- Genetic analysis
- Single-cell sequencing
Main finding
As reported in the abstract
Proteins identified as linked to DP
6
Original publication
Plasma proteomics identifies potential drug targets for diabetic polyneuropathy: Evidence from prospective cohorts and genetic analysis. Diabetes Obes Metab. Published 27 October 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →